作者
Lorenz Leitner, Aleksandre Ujmajuridze, Nina Chanishvili, Marina Goderdzishvili, Irina Chkonia, Sophia Rigvava, Archil Chkhotua, Giorgi Changashvili, Shawna McCallin, Marc P Schneider, Martina D Liechti, Ulrich Mehnert, Lucas M Bachmann, Wilbert Sybesma, Thomas M Kessler
发表日期
2021/3/1
期刊
The Lancet Infectious Diseases
卷号
21
期号
3
页码范围
427-436
出版商
Elsevier
简介
Background
Urinary tract infections (UTIs) are among the most prevalent microbial diseases and their financial burden on society is substantial. In the context of increasing antibiotic resistance, finding alternative treatments for UTIs is a top priority. We aimed to determine whether intravesical bacteriophage therapy with a commercial bacteriophage cocktail is effective in treating UTI.
Methods
We did a randomised, placebo-controlled, clinical trial, at the Alexander Tsulukidze National Centre of Urology, Tbilisi, Georgia. Men older than 18 years of age, who were scheduled for transurethral resection of the prostate (TURP), with complicated UTI or recurrent uncomplicated UTI but no signs of systemic infection, were allocated by block randomisation in a 1:1:1 ratio to receive intravesical Pyo bacteriophage (Pyophage; 20 mL) or intravesical placebo solution (20 mL) in a double-blind manner twice daily for 7 days, or …
引用总数
20202021202220232024254647432